CC-97540 + Lymphodepletion Chemotherapy
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Conditions
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Trial Timeline
Jul 9, 2026 → Dec 31, 2029
NCT ID
NCT07388277About CC-97540 + Lymphodepletion Chemotherapy
CC-97540 + Lymphodepletion Chemotherapy is a phase 1/2 stage product being developed by Bristol Myers Squibb for Antineutrophil Cytoplasmic Antibody-associated Vasculitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07388277. Target conditions include Antineutrophil Cytoplasmic Antibody-associated Vasculitis.
What happened to similar drugs?
1 of 1 similar drugs in Antineutrophil Cytoplasmic Antibody-associated Vasculitis were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07388277 | Phase 1/2 | Recruiting |
Competing Products
2 competing products in Antineutrophil Cytoplasmic Antibody-associated Vasculitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Avacopan + Placebo + Standard of Care | Amgen | Approved | 50 |
| FT819 + Fludarabine + Cyclophosphamide + Bendamustine | Fate Therapeutics | Phase 1 | 26 |